Wilson Sonsini Goodrich & Rosati represented ImmunityBio in the transaction. ImmunityBio, Inc., a clinical-stage immunotherapy company announced an up to $320 million royalty financing and equity...
Oberland Capital’s $320 Million Investment in ImmunityBio
ImmunityBio’s Acquisition of State-of-the-Art Manufacturing Plant in New York
Olshan Frome Wolosky represented ImmunityBio in the transaction. ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, has entered into a definitive agreement to acquire a leasehold interest in 409,000...